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ABSTRACT
HOX proteins define a family of key transcription fac-
tors regulating animal embryogenesis. HOX genes
have also been linked to oncogenesis and HOXA1
has been described to be active in several can-
cers, including breast cancer. Through a proteome-
wide interaction screening, we previously identified
the TNFR-associated proteins RBCK1/HOIL-1 and
TRAF2 as HOXA1 interactors suggesting that HOXA1
is functionally linked to the TNF/NF-B signaling
pathway. Here, we reveal a strong positive correlation
between expression of HOXA1 and of members of the
TNF/NF-B pathway in breast tumor datasets. Func-
tionally, we demonstrate that HOXA1 can activate NF-
B and operates upstream of the NF-B inhibitor IB.
Consistently, we next demonstrate that the HOXA1-
mediated activation of NF-B is non-transcriptional
and that RBCK1 and TRAF2 influences on NF-B are
epistatic to HOXA1. We also identify an 11 Histidine
repeat and the homeodomain of HOXA1 to be re-
quired both for RBCK1 and TRAF2 interaction and
NF-B stimulation. Finally, we highlight that activa-
tion of NF-B is crucial for HOXA1 oncogenic activity.
INTRODUCTION
HOX proteins constitute an evolutionary conserved family
of transcription factors critically involved in regulating bio-
logical processes during embryogenesis from patterning the
main body axis to coordinating organogenesis and differ-
entiation in all bilaterian animals (1). Mammalian genomes
contain 39 HOX genes which are clustered in four chromo-
somal loci and classified in 13 paralog groupswith respect to
their sequence similarity, their arrangement along the chro-
mosomes and the timing of their expression during devel-
opment (2,3).
HOXA1 is the firstHOX gene to be expressed in connec-
tion with gastrulation during embryogenesis. It is primar-
ily involved in hindbrain segmentation into rhombomeres.
Next,HOXA1 is required to determine the identity of rhom-
bomeres r4 and r5, and to specify the associated neural
crest. It also contributes to inner and middle ear develop-
ment, basioccipital bone formation and patterning of the
great arteries and outflow tract of the heart (4–6). Over
the last two decades, HOXA1 has been linked to adult can-
cers in breast, lung, liver, prostate and the oral cavity, as
well as to melanoma (7–12). In the context of breast cancer,
HOXA1 has been identified as a mammary epithelial onco-
gene, where its forced expression is sufficient to induce the
oncogenic transformation of immortalized human mam-
mary epithelial cells to aggressive in vivo carcinoma (11,13).
While the functions and to some extent target genes of
HOXA1 have been well documented, the molecular modal-
ities of HOXA1 activities remain scarcely characterized. So
far, two functional domains of the HOXA1 protein have
been clearly identified. The 60 amino acids long home-
odomain shared by all HOX proteins defines their DNA-
binding domain which folds into three -helices preceded
by a flexible N-terminal extension. The third helix and the
N-terminal extension are involved in specific contacts with
DNA (1,14). The so-called hexapeptide lies N-terminally to
the homeodomain extension. It is a six amino-acid longmo-
tif conserved inHOXproteins fromparalog groups 1 to 9 in-
volved in the interactionwith PBXproteins, the best charac-
terized HOX interactors which belong to the ‘Three Amino
acid Loop Extension’ (TALE) class of homeodomain tran-
scription factors. The integrity of the hexapeptide and the
interaction with PBX is crucial for HOXA1 transcriptional
activity in several reported cases. In fact, hexapeptide mu-
tations disrupting the HOXA1–PBX interaction lead to a
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phenocopy of the HOXA1 knockout in the mouse (15) as
well as to a loss of its oncogenic potential (16). In addition
to these well-characterized functional determinants, the N-
terminal moiety of human HOXA1 contains two histidine
(His) repeats of ten and five residues, respectively. These re-
peats are conserved among HOXA1 orthologs, although
the size of the longest His repeat varies, the mouse pro-
tein containing 11 and 5 His tracts, respectively. The func-
tion of these His repeats remains unexplored, but His repeat
length variations have been reported in cases of autism in
the Japanese population and in vitro expression of expanded
His-repeat variants ofHOXA1 resulted in a loss of coopera-
tive binding with PBX1, leading to nuclear protein aggrega-
tion, impaired neuronal differentiation and cell death (17–
19). His deletion within the HOXA1 sequence has also been
found in ventricular septal defect patients (20). Together,
these results suggest that these His repeats critically influ-
ence the function of the HOXA1 protein.
Protein–protein interactions mechanistically support the
function of regulatory proteins like transcription factors or
signal transducers. For the HOX family, the large reper-
toires of proteins HOX transcription factors are expected
to interact with still need to be identified. Only two exten-
sive searches for HOX interactors have been previously per-
formed focusing on UBX in Drosophila (21) and HOXA1
in mammals (22). From the proteome-wide yeast two hy-
brid screening we recently carried out to pinpoint HOXA1
protein partners, 41 candidate interactors were confirmed
by both affinity co-precipitation and Bimolecular Fluores-
cence Complementation assays. Most significantly, the vali-
dated HOXA1 interactors comprised proteins known to be
active in transcription regulation, but also proteins involved
in cell signaling like in focal adhesion, receptor tyrosine ki-
nase function, and the TGF/BMP and Tumor Necrosis
Factor (TNF)/Nuclear Factor kappa B (NF-B) pathways
(22).
The HOXA1 interactor proteins we identified as part
of the Tumor Necrosis Factor Receptor (TNFR) family
included RBCK1 (NCBI GeneID 10616, also known as
HOIL-1) and TRAF2 (NCBI geneID 7186). TNF signal-
ing is crucial for physiological processes like cell prolif-
eration, differentiation, apoptosis, immune response mod-
ulation and inflammation induction. Binding of the pro-
inflammatory cytokine TNF to TNFR initiates a sig-
naling cascade starting with the recruitment of TRADD
(TNF receptor-associated death domain) that further re-
cruits other proteins: cIAP1 and cIAP2 (cellular inhibitor
of apoptosis 1 and 2), RIPK1 (receptor-interacting protein
kinase 1), TRAF2 and TRAF5 (TNF receptor-associated
factors 2 and 5). RIPK1 is then poly-ubiquitinated allowing
docking of TAK1 (transforming growth factor--activated
kinase 1) in complex with TAB2 and TAB3 (TAK1 bind-
ing protein 2 and 3), and the IKK (Inhibitor of NF-B ki-
nase) complex subunits IKK, IKK andNEMO. The for-
mation of the IKK complex can be enhanced by the pres-
ence of the LUBAC complex, constituted of three proteins:
RBCK1 (HOIL-1), SHARPIN and HOIP (23–25). Oppo-
sitely, RBCK1 has also been suggested to display an in-
hibitory influence toward NF-B by negatively regulating
TAB2/TAB3 and targeting them for proteasomal degra-
dation, thereby impairing NF-B activation (26). Down-
stream of the IKK complex are the NF-B transcription
factors (p65/RelA, RelB, c-Rel, p50/NF-B1 and p52/NF-
B2) that can form different heterodimers, the most com-
mon being the p65/p50 heterodimer (27). Under basal con-
ditions, NF-B is held inactive in the cytoplasm by IB pro-
teins (28). Upon activation of the pathway, the phospho-
rylation of IKK and IKK by TAK1 acts as a switch;
activating NF-B by targeting IB for phosphorylation,
poly-ubiquitination and subsequent proteasome-dependent
degradation, allowing NF-B release and nuclear translo-
cation to engage transcriptional programs (29–31).
Since NF-B regulates more than 500 genes involved in
inflammation, cellular transformation, survival, prolifera-
tion, angiogenesis, invasion and metastasis (32,33), aber-
rant NF-B activation is frequently observed in adult
cancers in breast, lung, liver and the oral cavity, and in
melanoma (31,34,35), just like HOXA1 (7–11). Genetic al-
terations in multiple actors of the NF-B pathway have
been shown to be essential for cancer initiation. The E3
ubiquitin ligase RBCK1 has for example been reported as
implicated in breast cancer where it stimulates proliferation
by promoting the cell cycle (36) and TRAF2 is an onco-
gene that is amplified in 15% of human epithelial cancers
(37). Therefore, the NF-B pathway and HOXA1 expres-
sion could be functionally connected in the context of de-
fined cancers.
The validation of the direct interaction between HOXA1
and RBCK1 and TRAF2 led us to hypothesize that
HOXA1 can functionally connect to TNFR-signaling at
the protein-binding level, and thereby directly modulate
TNFR stimulation output. To possibly link this interaction
to tumorigenic processes and to highlight to what extent
HOXA1 expression could be correlated to the NF-B sig-
naling pathway, we analyzed public breast cancer datasets.
Next, we investigated whether HOXA1 could influence the
TNFR-mediated NF-B activation. In the present study
we first establish a highly significant positive correlation
between expression of HOXA1 and of members of the
TNF/NF-B signaling pathway in breast tumors. Then, we
demonstrate (i) that HOXA1 can activate NF-B both in-
dependently and in synergy with TNF stimulation, in a
specific and non-transcriptional fashion, (ii) that HOXA1
operates upstream of the NF-B inhibitor IB and triggers
IKK/ and p65 phosphorylation as well as p65 nuclear
translocation, (iii) that the RBCK1 and TRAF2 influences
on theNF-B response are epistatic toHOXA1, (iv) that re-
moval of the HOXA1 His repeat or homeodomain dimin-
ishes both its interactions with RBCK1 and TRAF2 and
its capacity to stimulate the TNF/NF-B pathway and (v)
that activation of NF-B is crucial for HOXA1 oncogenic
activity.
MATERIALS AND METHODS
Analysis of public breast cancer expression profiling datasets
All genome-wide expression profiling datasets of breast
cancer patients with a sample size >80 available in the pub-
lic domain (n = 20) were retrieved from the public Gene
Expression Omnibus (GEO) dataset on the NCBI web-
site (http://www.ncbi.nlm.nih.gov/geo/), and analyzed us-
ing R2: a genomics analysis and visualization platform de-
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veloped in the Department of Oncogenomics at the Aca-
demic Medical Center––University of Amsterdam (http:
//r2.amc.nl). The Chin-124 set was uploaded from EMBL
EBI (http://www.ebi.ac.uk/arrayexpress) under E-TABM-
158. Expression data (CEL files) were analyzed as described
previously (38). Briefly, gene transcript levels were deter-
mined from data image files usingGeneChip operating soft-
ware (MAS5.0 and GCOS1.0, from Affymetrix). Samples
were scaled by setting the average intensity of the middle
96% of all probe-set signals to a fixed value of 100 for ev-
ery sample in the dataset, allowing comparisons between
micro-arrays. Five datasets that showed noHOXA1mRNA
expression (GSE1456, -3494, -5462 and -12 093), or did not
yield HOXA1-correlating genes (GSE50948) were excluded
from further analysis.
The TranscriptView genomic analysis and visualization
tool within R2 was used to check if probe-sets had an
anti-sense position in an exon of the gene (http://r2.amc.nl
> genome browser). The probe-sets selected for HOXA1
(Affymetrix 214639 s at and Illumina 1700382) and for all
KEGG NF-B pathway genes (Supplementary Table S1)
meet these criteria. All expression values and other details
for the datasets used can be obtained through their GSE
or E number from the NCBI GEO and EBI ArrayExpress
websites, respectively.
Cell culture, transfection and treatment
MCF10A cells were maintained in Dulbecco’s modified Ea-
gle medium (DMEM) F12 (Invitrogen, Carlsbad, Califor-
nia, USA) supplemented with 5% Horse Serum (Invitro-
gen), 100 IU/ml penicillin and 100 g/ml streptomycin
(Sigma-Aldrich, Saint-Louis, Missouri, USA), 0.1 g/ml
cholera toxin (Sigma-Aldrich), 10 g/ml insulin (Sigma-
Aldrich), 0.5g/ml hydrocortisone (Sigma-Aldrich) and 20
ng/ml human epidermal growth factor (Invitrogen). MCF7
cells were maintained in DMEM 4.5 g/l D-glucose sup-
plemented with 10% fetal bovine serum (Invitrogen), 100
IU/ml penicillin and 100 g/ml streptomycin, 2 mM L-
glutamine (Invitrogen) and 1 mM sodium pyruvate. COS7
andHEK293T cells weremaintained inDMEM lowor high
glucose, respectively (Invitrogen) supplemented with Glu-
tamine, 10% fetal bovine serum (Invitrogen), 100 IU/ml
penicillin and 100g/ml streptomycin (Sigma-Aldrich). All
cells were maintained at 37◦C in a humidified 5% CO2 at-
mosphere.
MCF10A cells were transfected with X-treme Gene
9 DNA Transfection Reagent (Roche, Indianapolis, IN,
USA). MCF7, HEK293T and COS7 cells were transfected
with jetPRIME Transfection Reagent (Polyplus Transfec-
tion, Illkirch, France). All transfections were performed 24
h after plating and were carried out following the manufac-
turer’s instructions.
Where stated, Tumor Necrosis Factor  (TNF) or
Interleukin-1-beta (IL-1) (both from Sigma-Aldrich) were
added to the medium (25 ng/ml final concentration) 24 h
post-transfection for the indicated time.
Plasmids
Reporter plasmid pGL4.32[luc2P/NF-B-RE/Hygro]
(Promega, Madison, Wisconsin, USA) contains the lu-
ciferase reporter gene luc2P controlled by five copies of a 10-
nt NF-B responsive element corresponding to p65 binding
sites (39). Reporter plasmids pML-EPHA2-r4-Luc (40)
and pCMV-LacZ (41), expression plasmids for HOXA1WT
(pGIH-309), HOXA1QN-AA (pGIH-512), HOXA1WM-AA
(pGIH-328) Flag-HOXA2 (42) and PBX1 (pCMV-PBX1)
(43), the expression plasmid for PREP1 (44), the pEXP-
FLAG(Nter)-HOXA1, pEXP-VC155(Nter)-HOXA1,
pEXP-VN173(Nter)-HOXA1, pEXP-GST(Nter)-RBCK1,
pEXP-VN173(Nter)-RBCK1, pEXP-GST(Nter)-TRAF2
and pEXP-VN173(Nter)-TRAF2 vectors (22) andHOXA1
mutants generated by pentapeptide insertion mutagenesis
(45) were all described previously. The HOXA1 deletion
derivatives HOXA1Nter, HOXA111His, HOXA177-205,
HOXA1HD and HOXA1Cter were generated by over-
lapping polymerase chain reaction using the primers
listed in Supplementary Table S2 and swapping in pEXP
expression vectors for HOXA1 using the Gateway R©
system (Life Technologies, Carlsbad, California, USA)
following manufacturers’s instructions. All HOXA1
constructs were based on the canonical 336 amino acid
isoform (RefSeq NP 034579). Expression plasmids for
HOXA9, HOXB9 and HOXD9 were kind gifts from Dr
Deneen Wellik (University of Michigan, Ann Arbor, MI,
USA). HOXA9, HOXB9 and HOXD9 were entered in
the Gateway R© system (Life Technologies) to generate
N-terminally Flag-tagged proteins. The TRAF2 domi-
nant negative (TRAF2-DN) construct was obtained by
removing the 87 N-terminal amino acids from the human
TRAF2 cDNA. The remaining TRAF2 coding sequence
(amino acid residues 88–501) was amplified from the
pDEST-GST(Nter)-TRAF2 expression plasmid (22) and
inserted into the pDON-233 vector using the Gateway R©
BP recombination reaction (attB1F primer: GGGGAC
AACTTTGTACAAAAAAGTTGGC; attB2R primer:
GGGGACAACTTTGTACAAGAAAGTTGGGTA). By
Gateway R© LR recombination cloning, TRAF2-DN was
then transferred into the pDEST-Flag(Nter) destination
plasmid resulting in an expression plasmid encoding
TRAF2-DN protein tagged with an N-terminal Flag-
tag. Pre-tested shRNA constructs from the MISSIONR©
TRC2.0 shRNA library (Sigma-Aldrich) were used in
knockdown experiments. The constructs have unique,
non-overlapping homology with all target gene transcripts
described in http://www.ncbi.nlm.nih.gov/gene. The results
shown were obtained with constructs (TRCN0000)234978-
82 for HOXA1 (sh-#1-5, respectively), and (TRCN0000)
373433/373443 for TRAF2 (sh-#7/8). TRAF2 shRNA
constructs (46) were a kind gift from Dr Tse-Hua Tan (Na-
tional Health Research Institute, Zhunan, Taiwan). The
non-targeting hairpin control SHC002 (Sigma-Aldrich)
was used as a negative control. IB super repressor (IB-
SR) expression plasmid (47) was a kind gift from Dr John
Ashton (University of Rochester, New York, USA).
Luciferase assays
MCF10A cells seeded in 24-well plates (2.5 × 105 cells per
well) were transfected with 250 ng of luciferase reporter
plasmid, 250 ng of the expression plasmids and 50 ng of
constitutive reporter plasmid pCMV-LacZ for luciferase ac-
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tivity normalization. Empty vector was added when needed
so that all transfection reactions contained a total amount
of 1 g of DNA. Twenty-four hours after transfection, cell
lysis and enzymatic activity analysis were performed with
the -gal Reporter Gene Assay chemiluminescent (Roche
#11758241001) and the Luciferase Reporter Gene Assay
high-sensitivity (Roche #11669893001) kits following man-
ufacturer’s instructions. For each transfection, the constitu-
tively active pCMV-LacZ reporter was used as an internal
standard reporter to avoid experimental variations due to
transfection efficiency. The relative luciferase activity was
calculated as a luciferase/-galactosidase ratio. Results are
presented as means of three biologically independent dupli-
cates.
ELISA
MCF10A and MCF7 cells seeded in 6-well plates (6.0 ×
105 and 4.0 × 104 cells per well respectively) were trans-
fected with 500 ng expression plasmid and 2 g total DNA.
Medium supernatant was collected 48 h post-transfection.
Cells were rinsed with phosphate buffered saline (PBS)
and lysed in IPLS lysis buffer including Tris–HCl pH
7.5 20 mM, 120 mM NaCl, 0.5 mM ethylenediaminete-
traacetic acid, 0.5% NP40, 10% glycerol and protease in-
hibitor (#11873580001, Roche). IL-8 levels were quantified
using the BD OptEIA Human IL-8 ELISA Set (BD Bio-
science, East Rutherford, New Jersey, USA) following man-
ufacturer’s instructions. Total protein levels were quantified
with a Bicinchoninic Acid Assay (BCA) kit (Pierce). Results
are presented as means of three biologically independent
duplicates. In each experiment, the IL-8 level/protein ratio
is calculated as a percentage of the control.
Western blotting
MCF10A and MCF7 cells seeded in 6-well plates (6.0 ×
105 and 4.0 × 104 cells per well respectively) were trans-
fected as described above. Twenty-four hours after trans-
fection, or after TNF addition where stated, cells were
washed with PBS and lysed with IPLS lysis buffer. Cell
lysates were cleared by centrifugation for 5 min at 500 g
and the supernatant was collected. Proteins were boiled in
the presence of loading buffer, again centrifuged as above,
loaded on SDS-PAGE, transferred on nitrocellulose mem-
brane and processed for detection of specific proteins us-
ing antibodies against TAB2 (Cell Signaling #3745), TAB3
(Cell Signaling #14241), p-TAB2 (Ser372) (Cell Signal-
ing #8155), IKK (Cell Signaling #2682), IKK (Cell
Signaling #2370), p-IKK/ (Ser176/180) (Cell Signaling
#2697), IB (Cell Signaling #4814), p-IB (Cell Sig-
naling #2859), p65 (Cell Signaling #8242), p-p65 (Ser536)
(Cell Signaling #3033), FLAG (Sigma-Aldrich #F1804),
GST (Sigma-Aldrich #G7781), -actin (anti--actin-HRP,
Sigma-Aldrich #A3854). The secondary antibodies used
were goat anti-mouse IgG-HRP (Cell Signaling #7076) and
goat anti-rabbit IgG-HRP (Cell Signaling #7074). Results
are presented as a representative example of three biologi-
cally independent repetitions of the experiment.
Immunofluorescence
MCF10A cells seeded on glass coverslips in 24-well plates
(5.0 × 104 cells per well) were transfected as described
above. Twenty-four hours after transfection, or after TNF
addition when stated, cells were fixed for 10 min in 4%
paraformaldehyde (PFA). Coverslips were then sequen-
tially incubated with PBS-Triton X-100 for 5 min, and
with antibodies against p65 (SantaCruz Biotechnology #sc-
372), FLAG (Sigma-Aldrich #F1804) or GST (Sigma-
Aldrich #G7781) diluted in PBS–BSA 3% for 1 h. Sec-
ondary antibodies anti-rabbit-AlexaFluor-555 (Cell Signal-
ing #4413) and anti-mouse-AlexaFluor-488 (Cell Signaling
#4408) were next incubated in PBS–BSA 3% for 1 h. Nuclei
were stained with DAPI and coverslips were mounted with
Vectashield medium (Vector Laboratories, Cambridgeshire,
UK). Results are presented as a representative example
of three biologically independent repetitions of the exper-
iment.
Bimolecular fluorescence complementation
COS7 cells seeded on glass coverslips in 24-well plates
(1 × 105 cells per well) were transfected with 100 ng of
pDEST-VC155(Nter)-HOXA1 (WT or mutant) and 100 ng
of pDEST-VN173(Nter)-interactor (RBCK1 or TRAF2).
Twenty-four hours after transfection, cells were fixed with
4% paraformaldehyde for 30 min, rinsed three times with
PBS and once in TBS containing 0.1% Triton X-100. Glass
coverslips were mounted in Vectashield R©-DAPI medium.
Results are presented as a representative example of three
biologically independent repetitions of the experiment.
Quantification was performed using the ImageJ software.
Focus formation assay
MCF7 cells seeded in 6-well plates (2 × 105 cells per well)
were transfected as described above. Medium was changed
every 3 days. After 2 weeks, cultures were washed with PBS
and foci were counted under a binocular. Results are pre-
sented as three biologically independent repetitions of the
experiment.
MTT assay
MCF10A cells seeded in 96-well plates (5 × 103 cells per
well) were transfected as described above and medium was
changed 24 h after transfection. After 72 h of culture, cells
were incubated for 3 h in culture medium supplemented
with 0.5 mg/ml 3-(4,5-dimethylthiazolyl-2)-2,5 diphenylte-
trazoliumbromide (MTT) (Sigma-Aldrich#M2128). Plates
were centrifuged for 15 min at 1000 g, supernatant was
cleared and 200 l DMSO (Sigma-Aldrich #D2438) was
added to dissolve the formazan precipitate. Global cell
growthwas assessed bymeasuring the absorbance at awave-
length of 560 nm with background subtraction at 670 nm.
Results are presented as means of three biologically inde-
pendent repetitions of triplicates.
Affinity co-precipitation
HEK293T cells were seeded in 6-well plates (7 × 105 cells
per well) and were transfected with 500 ng of pDEST-
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Flag(Nter)-HOXA1 (wild-type or mutant) and 500 ng
of pDEST-GST(Nter)-interactor (RBCK1 or TRAF2).
Fourty-eight hours post-transfection, cells were rinsed with
PBS and lysed in lysis buffer. Cell lysates were cleared by
centrifugation for 5 min at 500 g and the cleared lysates
were incubated over-night on glutathione-agarose beads
(Sigma-Aldrich #G4510). The expression of Flag-tagged,
GST-tagged proteins and -actin was verified by western
blot before starting the co-precipitation experiments. After
overnight incubation of the proteins on glutathione beads,
proteins attached to the beads were dissociated from the
beads and loaded on SDS-PAGE, transferred on nitrocellu-
lose membrane and processed for detection of Flag-tagged
proteins. The intensity of the bands was quantified using
ImageJ software (http://imagej.nih.gov) and the signal ob-
tained for each Flag-HOXA1 fusion co-expressed with na-
tive GST was subtracted from the signal obtained with
that Flag fusion co-expressed with GST-RBCK1 or GST-
TRAF2. Results are a representative example of three bio-
logically independent repetitions of the experiment. Quan-
tification was performed using the ImageJ software.
Imaging
For p65 translocation assays, slides were analyzed by con-
focal microscopy (LSM 710, Zeiss). Images from BiFC and
for the cellular relocalization of HOXA1 in presence of
RBCK1, TRAF2 and TNFwere obtained by fluorescence
microscopy (Axioskop 2, Zeiss). Foci were observed under
a binocular (Leitz) and pictures were taken with a Fujifilm
Finepix S1 pro camera.
Statistical analysis
For the bio-informatic analyses in Figure 1 and Table 1,
HOXA1 mRNA expression was correlated to mRNA ex-
pression of other genes using a 2 log Pearson test. The sig-
nificance of a correlation is determined by t = R/sqrt((1-
r∧2)/(n-2)), where R is the correlation value and n is the
number of samples. Distribution measure is approximately
as t with n-2 degrees of freedom (see http://vassarstats.
net/rsig.html for details). Pathway enrichment analysis on
HOXA1-correlating genes was performed using the R2
KEGG Pathway Finder and standard settings, the NF-B
signaling pathway (ko04064) is as defined by KEGG (http:
//www.genome.jp/kegg/). KEGG pathway enrichment was
calculated using a 2 × 2 contingency table analysis, or chi-
square test with continuity correction. The P-value repre-
sents the significance of over-representation of the pathway
in the dataset. P < 0.05 was considered statistically signifi-
cant, unless otherwise stated.
All statistical analyses for lab experiments were per-
formed using the JMP11 software. Data from Luciferase
and ELISA assays were transformed as log(10) values prior
to the analysis. Results from Luciferase Assays were ana-
lyzed with a Tukey HSD test to compare grouped condi-
tions whereas a Dunnett test was performed to compare in-
dividual conditions. ELISA results were analyzed with a bi-
lateral one sample test for the mean. Results from MTT,
quantification of BiFC and quantification of Affinity co-
precipitation were analyzed with a unilateral one sample
test for the mean.
RESULTS
HOXA1 expression profiling analysis of public breast cancer
datasets
While characterizing the HOXA1 interactome, a set of in-
teractors corresponding to TNF-associated proteins was
identified and validated by additional protein–protein inter-
action assays (22). The validation of the direct interaction
between HOXA1 and RBCK1 and TRAF2 led us to hy-
pothesize that HOXA1 might by functionally linked to the
TNF/NF-B-elicited signaling.
HOXA1 and NF-B have both been associated to breast
cancer development. To determine to what extent HOXA1
expression could be correlated in vivo to genes involved in
the NF-B functional network, we analyzed breast cancer
datasets corresponding to genome-wide expression profiles.
To this end, we downloaded and selectedmRNA expression
data of breast cancer patient cohorts in the public domain
from the NCBI GEO depository using the R2 genomics
analysis and visualization platform as described in ‘Mate-
rials and Methods’ section. We examined 15 breast cancer
datasets in detail. We first collected all genes whose mRNA
expression was significantly correlated to that of HOXA1.
To obtain insight into signal transduction pathways within
this collection, we subjected these genes to a KEGG path-
way search. Table 1 shows that the NF-B pathway was sig-
nificantly over-represented within the HOXA1-correlating
genes in 12 of 15 datasets analyzed, more often than any
other signaling pathway. For the largest dataset, Bertucci-
266, 67 of the 87 NF-B pathway genes expressed in tumor
samples from this cohort were significantly associated with
HOXA1 expression (Figure 1). This suggests an association
with HOXA1 of almost the whole NF-B signal transduc-
tion network. The pattern from Bertucci-266 was repeated
in the other datasets: of 87 NF-B pathway genes with sig-
nificant negative or positive correlation to HOXA1 expres-
sion, 54 were consistently positively (n = 50) or negatively
(n = 4) associated with high HOXA1 mRNA expression in
6 or more of the 12 datasets (Supplementary Table S1 and
Supplementary Figure S1). Notably, NF-B-activating lig-
ands and cell surface receptors of all the different NF-B
upstream signaling routes are represented within these 50
positively correlated genes. As are the transcriptional target
genes from all different NF-B downstream effector path-
ways.
The 12 breast cancer datasets we analyzed are represen-
tative of the various breast cancer studies in the public do-
main. They have very different compositions with regard
to clinical grade, (molecular) subtype, tissue site, patient
age, etc. In addition, they were performed on three differ-
ent array platforms. We therefore propose that the results
observed are very robust.
We are aware that the NF-B pathway contains signal-
ing nodes that depend on protein modification or translo-
cation, especially in the intermediate signaling routes, that
cannot be detected usingmRNAexpression profiling.How-
ever, we observe a universal positive correlation with the
NF-B extracellular ligands and receptors, and a predomi-
nantly positive correlation with the NF-B transcriptional
target genes, that is consistent in the majority of the 12 ex-
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Figure 1. NF-B pathway genes with correlation to HOXA1 expression in breast cancer. Graphical overview of the NF-B pathway showing pathway
genes with a significant correlation to HOXA1 expression in the Bertucci-266 dataset. The KEGG NF-B pathway graph with constituent genes (in pale
green boxes with narrow border) is overlaid with boxes representing positively or negatively correlating genes (gene name on a green background with thick
green border, or on a yellow background with thick red border, respectively). More details on correlations are in Table 1. The overview shows an almost
comprehensive positive correlation with HOXA1 mRNA expression, strongly suggesting that the NF-B pathway is activated by HOXA1 in breast cancer
cells.
pression datasets we analyzed. Together, this strongly sug-
gests that the NF-B pathway is activated in the presence of
high HOXA1 expression in breast cancer cells.
HOXA1 triggers the activation of NF-B in a specific and
transcription-independent manner
To first address the ability of HOXA1 to stimulate the
NF-B pathway, we co-transfected human mammary ep-
ithelial cells MCF10A with a NF-B reporter construct
containing five copies of a NF-B responsive element
(PGL4.32[luc2P/NF-B-RE/Hygro], hereafter referred to
as ‘NF-B reporter’ (39) (Figure 2A) and a HOXA1 ex-
pression plasmid. This reporter assay revealed that HOXA1
expression triggered a 4-fold increased activity of the NF-
B reporter. This HOXA1-mediated activation of the NF-
B reporter appeared to be specific since other HOX pro-
teins like HOXA2, HOXA9, HOXB9 and HOXD9 were
also tested and could not significantly stimulate the re-
porter (Figure 2B). The specific effect exerted by HOXA1
on the NF-B reporter was further confirmed in a loss-of-
function model by transfecting MCF7 cells with different
shRNAs directed against HOXA1 (sh-HOXA1 #1 to #5).
sh-HOXA1 #2 and #3 significantly diminished both the
level of the HOXA1 protein and the activity of the NF-B
reporter, demonstrating that the activity of NF-B reporter
is enhanced by HOXA1. sh-HOXA1 #4 and #5 also pro-
voked a slight decrease in HOXA1 abundance and NF-B
reporter activity, although this did not reach statistical sig-
nificance (Figure 2C).
To determine whether the positive effect exerted by
HOXA1 was dependent on the transcriptional activity of
the protein, both wild-type and mutant proteins were used
on aHOXA1 target reporter derived from theEPHA2 gene,
pML-EPHA2-r4-luc (hereafter referred to as ‘HOXA1 re-
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Figure 2. Transactivation assays on both NF-B- and HOXA1-responsive reporters. (A) The NF-B reporter (PGL4.32[luc2P/NF-B-RE/Hygro]) con-
sists in a luciferase reporter geneLuc2P controlled by five copies of a 10-nt NF-B responsive element corresponding to p65 binding sites (GGGAATTTCC
orGGGACTTTCC). (B) The specificity of HOXA1 in activating the TNF/NF-B pathway was assessed using the NF-B reporter andHOXA1, HOXA2,
HOXA9, HOXB9 and HOXD9 expression plasmids in the human mammary epithelial cell line MCF10A. (C) The involvement of HOXA1 in NF-B ac-
tivation was assessed in a loss-of-function model by using sh-RNAs directed against HOXA1 in human breast cancer MCF7 cells. The HOXA1 protein
level was analyzed by western blot, and the NF-B activity was quantified by reporter Luciferase assay. (D) The HOXA1 reporter (pML-EPHA2-r4-luc)
consists in a luciferase reporter gene Luc2P controlled by 5 HOX-PBX binding sites defining the EPHA2 gene r4 enhancer (40). (E) The ability of HOXA1
to activate the HOXA1 reporter was assessed in MCF10A cells. As controls, transcriptionally inactive HOXA1WM-AA and HOXA1QN-AA mutant proteins
were tested. Expression plasmids encoding HOXA1 (wild-type, HOXA1WM-AA or HOXA1QN-AA) were transfected with or without expression plasmids
for the TALE cofactors PREP1 and PBX1. (F) Reporter assays performed inMCF10A cells using the NF-B reporter reveal that transcriptionally inactive
HOXA1 variants (HOXA1WM-AA, HOXA1QN-AA) are able to stimulate NF-B activity. (G) Similar experiments as in (F) were performed in MCF10A
cells with TNF addition (25 ng/ml for 24 h). Results are presented as a luciferase/-galactosidase ratio (relative luciferase activity) and correspond to
the means of three biologically independent duplicates ± SEM. Statistical analysis was performed (B and C) with reference to the condition involving the
NF-B reporter alone (NF-B reporter) as control or (E-G) with comparisons between groups (*P < 0.0001; ns = not significant).
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Table 1. Significant enrichment of the NF-B pathway among HOXA1-correlating genes in breast cancer datasets
HOXA1 mRNA expression was correlated to all KEGG NF-B pathway genes in 15 public breast cancer datasets. Genome-wide expression profiling
datasets of breast cancer patients available in the public domain were downloaded, selected and analyzed in R2 as described in the ‘Materials andMethods’
section. The first two columns represent dataset name and sample size. Columns 3–6 represent the KEGGNF-B pathway: over- or under-representation,
amount of genes correlating, amount of genes in the pathway expressed in the dataset and a P-value, respectively. The P-value represents the significance of
over-representation of the pathway in the dataset (results from a 2× 2 contingency table analysis, or chi-square test with continuity correction, significance
cut-off P < 0.05). With a P < 0.01 cut-off, the same 12 sets showed NF-B pathway enrichment, but with ∼20% fewer correlating genes. Columns 7–9
represent dataset platform, NCBI GEOGSE number and PubMed identifier, respectively. *ArrayExpress E-TABM-158. **Studies not yet published. The
KEGGNF-B pathway is significantly over-represented within HOXA1-correlating genes in 12 of 15 breast cancer datasets. For 7 of these 12, the NF-B
pathways was among the top 10 over-representedKEGGpathways. Only the Sotiriou-198 dataset shows an under-representation of NF-B pathway genes.
porter’) (40) (Figure 2D). The HOXA1WM-AA variant has
a substitution in the hexapeptide which makes the pro-
tein unable to interact with cofactors like PBX1 (15).
As already mentioned, PBX1 has appeared to be a cru-
cial cofactor for the transcriptional activity of HOXA1
on well-characterized target enhancers. The integrity of
the HOXA1 hexapeptide has also been shown necessary
to the developmental and oncogenic HOXA1 functions
(43). HOXA1QN-AA harbors a substitution in the home-
odomain which impairs DNA binding (43). In MCF10A
cells, both the HOXA1WM-AA and HOXA1QN-AA mutant
proteins, failed to activate the HOXA1 reporter as previ-
ously described (40). This therefore confirms these mutants
as transcriptionally inactive (Figure 2E). Surprisingly, all
HOXA1 versions enhanced the activity of theNF-Bdriven
reporter, supporting that HOXA1 could act on the pathway
in a transcription-independent manner. Moreover, addition
of PBX1 or the alternative TALEHOXA1 cofactor PREP1,
which normally allowHOXA1 to fully activate the HOXA1
reporter (43) had no effect on the activation of the NF-B
reporter by HOXA1 (Figure 2F).
Similar results were observed upon stimulation of the
pathway by TNF addition (Figure 2G). The TNF-
mediated activation of the NF-B reporter was about six
times higher in combination with HOXA1 than without
HOXA1. Since NF-B can also be activated upon stimula-
tion by other cytokines, the same experimentwas performed
by treating the cells with IL-1, leading to similar results
as with TNF addition (data not shown). This together
supports that HOXA1 activity synergized with cytokine-
mediated activation of NF-B.
To better understand at which level HOXA1 exerts its
influence in the TNF/NF-B signaling cascade, MCF10A
cells were co-transfected with expression plasmids for
HOXA1 and a non-degradable variant of IB (IB
S32/36A, hereafter called ‘IB-SR’) which acts as a repres-
sor of the pathway by preventing NF-B nuclear transloca-
tion (47,48). The HOXA1-mediated activation of the NF-
B reporter was fully suppressed by IB-SR (Figure 3A),
as was also the TNF-triggered activation of the reporter
(data not shown). This therefore demonstrates thatHOXA1
acts upstream of IB in the signaling cascade.
The ability of HOXA1 to enhance TNF-mediated NF-
B activation was further evaluated by investigating the
phosphorylation status of NF-B signaling proteins upon
TNF stimulation in the presence or in the absence of
HOXA1.MCF10A cells were transfected with a vector cod-
ing for HOXA1 or an empty vector as negative control,
and were treated with TNF 24 h later. The cells were
harvested at different time-points to evaluate the levels of
both total and phosphorylated TAB2 (Ser372), IKK/
(Ser176/180), IB (Ser32) and p65 (Ser536) using western
blot analysis.Whereas whole protein levels of TAB2, TAB3,
IKK/, IB and of p65 were similar between cells trans-
fected for HOXA1 or with the negative control, expression
of HOXA1 led to increased levels of phosphorylated TAB2
(Ser372), phosphorylated IKK/ (Ser176/180), phospho-
rylated IB (Ser32) and phosphorylated p65 (Ser536)
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Figure 3. Effect of HOXA1 on the NF-B pathway. (A) The effect of a super repressor version of IB (IB-SR) on the HOXA1-mediated activation of
the NF-B reporter was assayed in MCF10A cells. Results are presented as a luciferase/-galactosidase ratio (relative luciferase activity) and correspond
to the means of three biologically independent duplicates ± SEM. Statistical analysis was performed with reference to the condition involving the NF-
B reporter alone (NF-B reporter). (B) Western blot showing TAB2, TAB3, p-TAB2 (Ser372), IKK, IKK, p-IKK/ (Ser176/180), IB, p-IB
(Ser32), p65 and p-p65 (Ser536) proteins from MCF10A cells transfected with a FLAG-HOXA1 expression plasmid or with a negative control, and
treated with TNF (25 ng/ml) for 0, 10, 15, 20, 30 or 45 min. A total of 25 ng/ml was chosen from a range of 0, 6.25, 12.5, 25, 50, 75 or 100 ng/ml as
the lowest TNF concentration to give full reporter activation. At this TNF concentration, reporter activation is comparable between 30 min and 24 h
(not shown). A total of 250 ng HOXA1 plasmid was chosen as the optimal transfection dose from a range of 0, 50, 100, 250, 500 or 750 ng as the lowest
HOXA1 dose to give full reporter activation (not shown). Detection of -actin was used as loading control. Bands corresponding to detected proteins
were cropped for the sake of presentation but all samples were processed in parallel, being run together on single protein gels. The provided blots are
representative of three biologically independent experiments. (C) p65 nuclear translocation was analyzed in MCF10A cells by confocal microscopy. The
images represent the cellular localization of endogenous p65 (red channel) and FLAG-HOXA1 (green channel) from representative confocal Z-section
at 120 times magnification. Cell nuclei were stained with DAPI (blue channel). (D) ELISA quantification of IL-8 secretion upon HOXA1, IB-SR, and
HOXA1 and IB-SR expression, or after TNF or IL-1 addition to MCF10A cells. IL-8 secretion was normalized to the protein content of the cell-
culture well and data were calculated using the mean absorbance of two wells. The negative control was set to 100% and statistical analysis was carried out
using the negative control as control level (*P < 0.0001). This is a representative experiment of three biologically independent duplicates ± SEM. (E) The
involvement of HOXA1 in triggering IL-8 secretion was assayed as in (D) using sh-HOXA1 vectors in MCF7 cells. The positive control was set to 100%
and statistical analysis was carried out using the positive control as control level (*P < 0.0001). This is a representative experiment of three biologically
independent duplicates ± SEM.
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compared to the negative control upon TNF stimula-
tion. The phosphorylated forms of TAB2 and IKK/
were detected earlier and were more abundant in cells ex-
pressing HOXA1 compared to cells transfected with the
negative control. The phosphorylated forms of IB and
p65 were detected for a longer period in cells expressing
HOXA1 (Figure 3B and Supplementary Figure S2). These
results therefore show that HOXA1 could stimulate TAB2,
IKK/, IB and p65 phosphorylation in combination
with TNF.
As mentioned above, NF-B activation results in nuclear
translocation of NF-B dimers, the most common being
p65/p50 dimers. We therefore investigated by immunoflu-
orescence whether HOXA1 could trigger p65 relocaliza-
tion to the nucleus in MCF10A cells (Figure 3C). Whereas
p65 was located in the cytoplasm in cells transfected with
an empty vector (negative control), p65 nuclear translo-
cation was observed in cells treated 15 min with TNF.
Cells expressing HOXA1 displayed both a cytoplasmic and
a nuclear p65 localization. This confirms that the HOXA1-
dependent NF-B activation can be associated to p65 nu-
clear translocation.
Finally, we evaluated the ability of HOXA1 to stimu-
late IL-8 secretion as a downstream effect of NF-B tar-
get gene activation. Transfection of HOXA1 in MCF10A
cells provoked a more than 2-fold increase in IL-8 secre-
tion as detected in the culture medium. Similarly, TNF
and IL-1 addition resulted in a high level of IL-8 secretion.
As expected, co-expression of HOXA1 and IB-SR signif-
icantly reduced the positive effect of HOXA1 on IL-8 pro-
duction (Figure 3D). The specificity of HOXA1 to trigger
IL-8 secretion was confirmed in a loss-of-functionmodel by
transfecting vector coding for sh-HOXA1 in MCF7 cells.
As observed for the Luciferase assays, sh-HOXA1 #2 and
#3 decreased the HOXA1-related IL-8 levels compared to
the positive control corresponding to non transfected cells
showing endogenous HOXA1 expression. Transfection of
sh-HOXA1 #1, #4 and #5 led to IL-8 levels similar to the
positive control (Figure 3E).
Taken together, these data show that HOXA1 can ac-
tivate NF-B in a specific and transcription-independent
manner, acting upstream of IB in the signaling cascade
and triggering TAB2, IB, IKK/ and p65 phosphory-
lation, p65 nuclear translocation andNF-B target gene ac-
tivation.
The HOXA1-interactors RBCK1 and TRAF2 are epistatic
to HOXA1 in modulating the activation of NF-B
Since RBCK1 and TRAF2 were identified as direct
HOXA1 interactors (22), the ability of those proteins to
modulate HOXA1 activity on NF-B was evaluated in
MCF10A cells. Activity tests were performed using an NF-
B reporter, with each interactor alone or in combination
with HOXA1. RBCK1 did not activate the NF-B reporter
whereas TRAF2 triggered a high increase of its activity.
Surprisingly, RBCK1, that is reported in lots of studies
as a subunit of the LUBAC complex that stabilizes the
TRADD-dependent complex and enhances formation of
the IKK complex (24,25), repressed the stimulatory activ-
ity of HOXA1 on the NF-B reporter. In addition, RBCK1
also inhibited the NF-B reporter activation mediated by
TRAF2. This suggests that RBCK1 exerts an epistatic ac-
tivity toward both HOXA1 and TRAF2 (Figure 4A). These
data therefore support the hypothesis that HOXA1 is im-
plicated in the TNF/NF-B pathway upstream or at the
level of RBCK1. Similar results were obtained upon stimu-
lation of the pathway by TNF (Figure 4B) or IL-1 (Fig-
ure 4C). Also, the results observed were similar whether the
wild-type HOXA1 or the HOXA1WM-AA or HOXA1QN-AA
mutants were expressed (data not shown).
Regarding the functional interaction between HOXA1
and TRAF2, HOXA1 did not further enhance the TRAF2-
mediated reporter activation that was already fully acti-
vated by TRAF2. To assess whether TRAF2 is epistatic
to HOXA1 in NF-B signaling, we generated a dominant
negative construct of TRAF2 (hereafter called ‘TRAF2-
DN’) by removing its N-terminal RING finger domain.
This abrogates its NF-B activation capability (49–51). In-
terestingly, TRAF2-DN inhibited the stimulatory effect of
HOXA1 on theNF-B reporter, as well as the activation ex-
erted by TRAF2 (Figure 4D). Similarly, co-transfection of
HOXA1 with vectors coding for sh-RNAs directed against
TRAF2 resulted in a decreased ability for HOXA1 to trig-
ger NF-B activation. (Figure 4E). Since HOXA1 is unable
to activate NF-B in the presence of TRAF2-DN or sh-
TRAF2, this suggests that HOXA1 acts upstream or at the
level of TRAF2 in the signaling cascade.
Quantification of IL-8 secretion was then performed to
deeper characterize the effect of RBCK1 and TRAF2 on
the HOXA1-mediated NF-B activation. As already ob-
served, HOXA1 expression led to increased IL-8 produc-
tion. Addition of RBCK1, alone or in combination with
HOXA1, led to an IL-8 level that was similar to the negative
control. Consistent with our observations with the NF-B
reporter, the IL-8 level was greatly increased by TRAF2,
whether HOXA1 was co-expressed or not (Figure 4F).
Finally, the influence of RBCK1 andTRAF2 onHOXA1
cellular localization was evaluated by immunofluorescence.
In MCF10A cells transfected with HOXA1 only, the pro-
tein was exclusively located in the nucleus. Co-transfection
of FLAG-HOXA1 and GST-RBCK1 or GST-TRAF2 re-
sulted in both nuclear and cytoplasmic localization of
HOXA1. In TNF-treated cells, HOXA1 was also located
in the nucleus and in the cytoplasm of most cells (Figure
5). These observations strongly suggest that HOXA1 is re-
cruited from the nucleus to the cytoplasmic compartment
of the cells by RBCK1 and TRAF2 or upon activation of
the pathway by TNF.
In conclusion, our data demonstrate that RBCK1 and
TRAF2 have opposite epistatic effects on the HOXA1 acti-
vation of the NF-B pathway and influence the cellular lo-
calization ofHOXA1. Furthermore,HOXA1 is inhibited by
RBCK1 and acts upstream or at the level of both RBCK1
and TRAF2 in the signaling cascade.
The 11-His repeat and the homeodomain of HOXA1 are es-
sential for NF-B activation
To identify the structural determinants involved in the
HOXA1-mediated activation of NF-B, we used HOXA1
mutants that were previously generated by random pen-
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Figure 4. Effect of RBCK1 and TRAF2 on the HOXA1-mediated activation of the NF-B reporter. (A) Activity tests were performed using the NF-B
reporter where each interactor was transfected alone or in combination with HOXA1. Results are presented as a luciferase/-galactosidase ratio (relative
luciferase activity) and correspond to the means of three biologically independent duplicates ± SEM. (B) The same experiment was performed after
stimulation of the pathway with TNF. The experiments were performed with 30 min or 24 h TNF stimulation, with similar results (not shown, see also
legend to Figure 3B). (C) The same experiment was performed after stimulation of the pathway with IL-1. (D) Effect of a dominant negative version
of TRAF2 (TRAF2-DN) on the HOXA1-mediated activation of the NF-B reporter. (E) Activity tests were performed using the NF-B reporter where
HOXA1 was transfected alone or in combination with sh-TRAF2 expression vectors. (F) ELISA quantification of IL-8 secretion upon RBCK1, TRAF2
and HOXA1 expression. IL-8 secretion was normalized to the protein content of the cell-culture well and data were calculated using the mean absorbance
of two wells. The negative control was set to 100% and statistical analysis was carried out using the negative control as control level (*P < 0.0001). This is
a representative experiment of three biologically independent duplicates ± SEM. The experiments for (A and D) were not performed at the same time, so
variations in cell culture (e.g. passage number, confluence) and/or transfection could be different. All the experiments were performed in MCF10A cells.
Data were obtained, processed and represented as in Figure 2. Statistical analysis was carried out (E) with the condition involving the NF-B reporter
alone (NF-B reporter) as control level, or (A–D; F) using comparisons between groups. (*P < 0.0001; ns = not significant).
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Figure 5. Effect of RBCK1, TRAF2 and TNF on the HOXA1 intracel-
lular localization. Immunofluorecence was performed after transfection of
MCF10A cells with FLAG-HOXA1 alone or in combination with GST-
RBCK1 or GST-TRAF2, or upon TNF treatment (25 ng/ml, 15 min).
Scale bars correspond to 0.02 mm.
tapeptide insertion mutagenesis (45). All the insertion mu-
tants activated the NF-B reporter to similar levels as
wild-type HOXA1 (Supplementary Figure S3). Consistent
with the results obtained for the transcriptionally inac-
tive HOXA1QN-AA protein mutated in the homeodomain,
HOXA1 insertionmutants P14, P15 andP16, showing a dis-
rupted homeodomain, were not affected in their ability to
activate the NF-B reporter. Interestingly, mutants display-
ing a loss-of-activity on a HOXA1 reporter (P1, P5, P13,
P15, P16, P17) (45) could still activate the NF-B reporter
as efficiently as wild-type HOXA1. This again confirms the
transcription-independent activity of HOXA1 in the NF-
B signaling pathway.
We next generated a set of HOXA1 deletion mutants
(Figure 6A). Evaluating their expression levels by west-
ern blot in the soluble fraction of cell lysates revealed
that the HOXA1Nter, HOXA111His and HOXA1HD pro-
teins were expressed at similar levels as wild-type HOXA1,
whereas HOXA177-205 and HOXA1Cter showed lower ex-
pression (Figure 6B).
The HOXA1Nter and HOXA1Cter mutants displayed
similar activity as thewild-type on theNF-B reporter (Fig-
ure 6C). HOXA177-205 displayed a slightly decreased activ-
ity compared to the wild-type which may be caused by it
lower expression level. In striking contrast, HOXA111His,
deleted for the 11-His repeat, and HOXA1HD, devoid of
its homeodomain, both lost their ability to activate the
NF-B reporter. However HOXA111His was as active as
the wild-type on the HOXA1 reporter (Figure 6D). This
therefore demonstrates that HOXA111His has not lost its
ability to activate transcription but has lost its capacity to
non-transcriptionallymodulate theNF-Bpathway. Other-
wise, consistent with the known involvement of the home-
odomain in DNA binding and activation of transcription,
HOXA1HD could not activate the HOXA1 reporter. The
ability of the HOXA1 deletion mutants to activate the NF-
B pathway was again evaluated by testing their capacity
to trigger IL-8 secretion. Consistently with their hypoactive
effects observed on the NF-B reporter, HOXA111His and
HOXA1HD caused lower IL-8 secretion levels compared
to the wild-type HOXA1 protein (Figure 6E).
Together, these data indicate that both the 11-His repeat
and the homeodomain of HOXA1 are important to estab-
lish the molecular contacts that initiate the indirect and
non-transcriptional HOXA1-mediated NF-B activation.
HOXA111His and HOXA1HD show decreased interaction
with RBCK1 and TRAF2
We wanted to determine whether a molecular interac-
tion between HOXA1 and RBCK1 or TRAF2 underpins
their functional interaction in modulating NF-B activ-
ity, and whether the hypoactive effect of HOXA111His and
HOXA1HD was correlated with a reduced interaction with
RBCK1 or TRAF2. This was addressed by affinity co-
precipitation assays and Bimolecular Fluorescence Com-
plementation (BiFC).
For the co-precipitation assays, FLAG-tagged wild-type
or mutant HOXA1 proteins were co-expressed with GST-
tagged RBCK1 or GST-tagged TRAF2 in HEK293T cells.
The expression level of FLAG- and GST-tagged proteins
was controlled (with -actin detection as loading control)
and the background binding of HOXA1-FLAG or mu-
tant HOXA1-FLAG to the glutathione-agarose beads af-
ter co-expression with native GST was low. Although these
experiments await further quantification by e.g. titration
of input protein, we propose that the HOXA111His and
HOXA1HD mutants appeared to interact less efficiently
with both RBCK1 and TRAF2, in comparison to the pos-
itive control loaded on the same gel (Figure 7A and B). We
realize that our HOXA1 binding experiments are based on
HOXA1 over-expression, and would need final confirma-
tion by assays using endogenously expressed HOXA pro-
tein. However, the very similar–– but opposite effects of en-
dogenous HOXA1 knockdown on NF-B reporter activity
and IL-8 secretion lead us to propose that also endogenous
HOXA1 could interact with RBCK1 and TRAF2.
For BiFC, the HOXA1 mutants were fused C-terminally
to the C-terminal 155 amino acids of the Venus fluorescent
protein (VC155) while TRAF2 and RBCK1 were fused C-
terminally to the N-terminal 173 amino acids of the Venus
(VN173) as previously described (22). Detection of fluo-
rescence in COS7 cells transfected with the VN173 and
VC155 fusion proteins shows that the functional Venus has
been reconstituted, indicating that the proteins fused to
each Venus moiety interact. As negative controls, we as-
sessed the fluorescence resulting from the expression of un-
fused Venus moieties in combination with the counterpart
fusion proteins. Combining VC155-HOXA1, containing ei-
ther HOXA1 wild-type or deletion mutants, with unfused
VN173 protein led to only low, background fluorescence.
Similarly, VN173-RBCK1 and VN173-TRAF2 only pro-
vided background fluorescence while co-expressed with un-
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Figure 6. Impact of HOXA1 deletions on NF-B activation. (A) Schematic representation of HOXA1 deletion derivatives. The wild-type (WT) protein
contains two functional domains: the homeodomain (HD) and the hexapeptide (HP). It also contains two His rich regions: an 11-Histidine repeat (11-His)
at the N-terminal side and a 5-His repeat (5-His) between the 11-His repeat and the hexapeptide. HOXA1Nter lacks the first 40 amino acids; HOXA111His
lacks the complete 11-His repeat; HOXA1HD lacks the homeodomain; HOXA177-205 lacks the amino acids between the 11-His repeat and the hexapep-
tide; HOXA1Cter is devoid of the C-terminal 48 amino acids. (B) HOXA1 deletion mutant expression was analyzed by western blot. Samples were
centrifuged before use and only the soluble fraction was analyzed on gel. We did not find HOXA1 protein in the insoluble fraction (C and D) Activity
of the HOXA1 deletion mutants on the NF-B and HOXA1 reporters, respectively. Results are presented as a luciferase/-galactosidase ratio (relative
luciferase activity) and correspond to the means of three biologically independent duplicates ± SEM. (E) ELISA quantification of IL-8 secretion upon
expression of HOXA1 deletion mutants. Results were obtained as presented in the legend to Figure 3D. All the experiments were performed in MCF10A
cells.
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Figure 7. Interaction assays. (A) Co-purification of proteins on glutathione-agarose beads. Expression plasmids for FLAG-taggedWT andmutantHOXA1
were co-transfectedwithGST-taggedRBCK1 andGST-tagged TRAF2 inHEK293T cells.Western blot analysis was used to detect FLAG-taggedHOXA1,
RBCK1-GST, TRAF2-GST and -actin proteins from cell extracts before purification (‘Input’). After purification, we retrieved comparable levels of
RBCK1-GST and TRAF2-GST from the beads (not shown). Samples were centrifuged before use and only the soluble fraction was analyzed on gel. We
did not find HOXA1 protein in the insoluble fraction. Data presented are representative examples; the experiments were performed three times reaching
similar results. (B) Quantification of the FLAG-tagged Hoxa1 protein bands retrieved from the three co-purification experiments. Results are presented as
ratios between the mutant and WT HOXA1 co-precipitation, after subtraction of the signal corresponding to the background co-precipitation obtained
with native GST and correspond to means ± SEM (n = 3). Values were statistically analyzed using an Unilateral one sample test for the mean (*P
< 0.0001). (C) Bimolecular Fluorescence Complementation assay. COS7 cells were transfected with combinations of expression plasmids for VN173,
VC155, VC155-HOXA1, VC155-HOXA111His, VC155-HOXA1HD, VN173-RBCK1 or VN173-TRAF2. Upon co-expression of VN173-HOXA1 and
VC155-HOXA1, the Venus protein is reconstituted and becomes fluorescent as HOXA1 can dimerize (65). Fluorescence complementation does not occur
when unfused VN173 and VC155 are co-expressed. Co-expression of VC155-HOXA1 or VC155-HOXA1 deletion derivatives with unfused VN173 serve
as controls for background signal. Co-expression of VC155-HOXA1 or VC155-HOXA1 mutants with VN173-RBCK1 or VN173-TRAF2 reveals that
both HOXA111His and HOXA1HD interact less efficiently with RBCK1 or TRAF2. This is a representative example of three biologically independent
experiments. Although the relative expression levels of the three VC155-HOXA1 fusion proteins were not determined in this experiment, we propose that the
comparable expression levels of the three native HOXA1 proteins (Figure 6B) suggest that also the VC155-HOXA1 fusions are expressed at similar levels.
Scale bars correspond to 0.02 mm. (D) BiFC quantification. The integrated density corresponds to the measurement of fluorescence intensity according
to the ImageJ software. The integrated density of VC155-HOXA1-VN173-RBCK1 or VC155-HOXA1-VN173-TRAF2 was set to 100% and was used as
control level for the statistical analysis (*P < 0.0001). Results of three biologically independent repetitions of the experiment were used for quantification.
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fused VC155 (Figure 7C). As a positive control, the estab-
lished HOXA1-HOXA1 interaction assayed with VN173-
HOXA1 and VC155-HOXA1 fusions generated a strong
signal. Finally, the VC155-HOXA1 deletion mutants co-
expressed with VN173-RBCK1 or with VN-173-TRAF2
displayed lower fluorescent signal intensities compared to
the wild-type VC155-HOXA1 (Figure 7C) and we quanti-
fied this loss of interaction for both deletion derivatives in
the BiFC assay (Figure 7D).
Taken together, both interaction assays for HOXA111His
and HOXA1HD indicate that these deletions impaired the
capacity of HOXA1 to interact with TRAF2 and RBCK1.
NF-KB activation is crucial for HOXA1 oncogenic activity
As HOXA1 is a human mammary epithelial oncogene, the
need for HOXA1 to activate the NF-B pathway to exert
its oncogenic potential was then assessed. Cell-to-cell con-
tacts formed by normal epithelial cells when they reach con-
fluence operate to suppress further cell proliferation. Tu-
mor cells are capable to lose this contact inhibition, giv-
ing rise to focus formation (16,52). The ability for endoge-
nous HOXA1 to evade growth suppressors and trigger fo-
cus formation was tested by transfecting MCF7 cells with
a vector coding for sh-HOXA1. As illustrated in Figure
8A, after two weeks in culture, HOXA1 positive MCF7
cells displayed numerous foci while the downregulation of
HOXA1 abrogated focus formation. To next test whether
the HOXA1-mediated stimulation of focus formation re-
quired the NF-B pathway, MCF7 cells were transfected
with the pathway inhibitor IB-SR.Most strikingly, MCF7
cells transfected with IB-SR did not enhance focus forma-
tion, just like with the sh-HOXA1 (Figure 8A). This sup-
ports that focus formation related to the oncogenic poten-
tial of HOXA1 relies on the NF-B pathway.
It has been previously demonstrated that overexpression
of HOXA1 in human mammary epithelial cells leads to
an increased proliferation rate (16,53). Its capacity to in-
crease proliferation independently of the NF-B pathway
was then evaluated by transfecting MCF10A cells with a
vector coding for HOXA1 alone or in combination with
IB-SR. HOXA1 overexpression led to an increased pro-
liferation rate of the cells, as already demonstrated whereas
co-transfection ofHOXA1 and IB-SRdid not enhance cell
proliferation which was similar to the negative control (Fig-
ure 8B). This demonstrates that HOXA1 cannot stimulate
the proliferation of human breast cells if the NF-B path-
way is blocked.
In conclusion, activation of theNF-B pathway is crucial
for HOXA1 to mediate oncogenicity.
DISCUSSION
HOX proteins have been extensively studied and by now
widespread knowledge exists on their sequence and struc-
ture, as well as on their target genes. In contrast, the large
range of proteins that HOX transcription factors can be ex-
pected to interact with remain scarcely identified. We there-
fore performed an interactome screenwithHOXA1 and sig-
nificantly ended upwith several interactors that are involved
in the TNF/NF-B pathway. In this study, we first demon-
strated a highly significant positive correlation between ex-
pression of HOXA1 and of members of the TNF/NF-
B signaling pathway in breast tumor public datasets, in-
cluding extracellular ligands, receptors, signal transducers
and adaptor molecules from different converging signaling
routes leading to NF-B activation. Also the NF-B tran-
scription factor family members and some of their tran-
scriptional target genes were found in this analysis. In addi-
tion to the HOXA1 and TNF/NF-B correlation in breast
tumor datasets, we demonstrated in cell models, (i) that
HOXA1 can activateNF-Bboth independently and in syn-
ergywithTNF stimulation, (ii) thatHOXA1 activatesNF-
B in a specific and non-transcriptional fashion, (iii) that
HOXA1 operates upstream of the NF-B inhibitor IB,
by triggering TAB2 (Ser372), IKK/ (Ser176/180), IB
(Ser32) and p65 (Ser536) phosphorylation and p65 nuclear
translocation, (iv) that RBCK1 and TRAF2 influences on
the NF-B response are epistatic to HOXA1 and finally (v)
that the 11-His repeat and the homeodomain ofHOXA1are
important for the functional interaction between HOXA1
and NF-B activation as well as for the molecular interac-
tion betweenHOXA1 andRBCK1 andTRAF2. Finally, we
also showed that the HOXA1-mediated cell-proliferation
and loss of contact inhibition are abrogated upon NF-B
pathway inhibition. Together our data demonstrate that the
HOXA1 transcription factor can fulfill non-transcriptional
functions as a stimulator of TNF signaling acting upstream
or at the level of both RBCK1 and TRAF2 and leading to
NF-B activation in a context meaningful to breast tumori-
genesis.
This study set out using in silico data in the public do-
main. The consistent over-representation of the NF-B sig-
naling pathway among the signaling routes correlated to
HOXA1 expression, and the highly significant positive cor-
relations between most genes in the NF-B pathway and
HOXA1 expression in breast tumor samples suggests a
marked implication of HOXA1 in this pathway in the con-
text of breast cancer pathogenesis. HOXA1 has already
been associated to breast cancer development in multiple
studies. Its forced expression is sufficient to induce the onco-
genic transformation of immortalized human mammary
epithelial cells to aggressive in vivo carcinoma (11,13,53).
HOXA1 can alsomodulate the p44/42MAPkinase, STAT3
and STAT5B pathways to mediate the oncogenic trans-
formation of human mammary epithelial cells and regu-
lates Bcl-2, hTERT and c-Myc, all genes involved in can-
cer development (13,53). We previously demonstrated that
the overexpression of HOXA1 in MCF7 human mammary
epithelial cancer cells enhanced their proliferation, their
anchorage-independent growth and their loss of contact
inhibition, which are recognized hallmarks of oncogenesis
(16,52,54). The functional connection we highlighted here
between HOXA1 and NF-B is meaningful in the con-
text of breast oncogenesis. Constitutive activation of NF-
B transcription factors p65 and p50 has been widely re-
ported in breast cancers and has been associated with cell
survival, proliferation, angiogenesis, metastasis and chemo-
resistance (55–60). TRAF2 also has been reported as an
oncogene in epithelial cells (37). The existence of cross-talks
between NF-B and other transcription factors and regula-
tory molecules is also well established for several kinds of
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Figure 8. Oncogenicity tests. (A) Foci formation assay was performed by transfecting MCF7 cells with empty vector (negative control), IB-SR or sh-
HOXA1 #3. After 2 weeks in culture, foci formation was observed for the negative control (white arrowheads) whereas cells transfected with IB-SR or
sh-HOXA1 did not form foci. Pictures presented were taken from three biologically independent experiments. Scale bar corresponds to 0.02 mm. (B) MTT
assay was performed by transfection MCF10A cells with HOXA1 alone or in combination with IB-SR. Global cell growth was determined by MTT
assay. Results are presented as a proliferative index obtained by calculating the mean absorbance of each condition and corresponds to the mean of three
biologically independent triplicates ± SEM. Statistical analysis was carried out using the ‘HOXA1’ condition as control level (*P < 0.0001).
cancers that display NF-B activation (61). Therefore, in
addition to oncogenic processes and oncogenes which have
been shown to be controlled by HOXA1, we suggest here
that HOXA1 also activates the NF-B pathway to promote
oncogenesis in mammary epithelial cells.
As mentioned above, RBCK1 (also known as HOIL-
1), together with HOIP and SHARPIN, is a part of the
LUBAC complex which stabilizes the TRADD-dependent
complex and enhances formation of the IKK complex (23–
25).While investigating the influence of RBCK1 on the pos-
itive effect exerted by HOXA1 on NF-B, we unexpectedly
observed that oppositely to what is generally described in
the literature RBCK1 has an inhibitory influence onNF-B
activity which was epistatic to both HOXA1 and TRAF2-
mediated stimulation. Using over-expression of HOXA1 or
TRAF2, we hereby confirm the ability of the E3 ubiquitin
ligase RBCK1 to display the inhibitory effect toward NF-
B which has already been suggested by others (26). In that
study, it was demonstrated that RBCK1 physically interacts
with TAB2/3 to target them to a proteasome-dependent
 at FU
N
D
P - BU
M
P on O
ctober 11, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2016, Vol. 44, No. 15 7347
degradation, thereby inhibiting NF-B activation. We can-
not currently report on the mechanism by which HOXA1
interaction with RBCK1, or with TRAF2 regulates NF-B
signaling in our experiments. Possibly, HOXA1 regulates
the TRAF2 ubiquitin ligase activity. Further conclusions
await studies into the ubiquitin signaling that could be in-
volved.
The NF-B and HOXA1 interconnection is reinforced
by their functional relationship with miR-10a. HOXA1 has
been reported as a direct downstream target of mirR-10a.
During megakaryocytic differentiation, miR-10a is sharply
down-regulated and HOXA1 is correlatively upregulated
(62). In the chronic pro-inflammatory state of arterial en-
dothelial cells in atherosclerosis regions, local miR-10a ex-
pression is lowered whereas HOXA1 expression is up-
regulated (63). In human aortic endothelial cells, miR-10a
inhibition causes HOXA1 upregulation both at the mRNA
and protein levels. Strikingly, NF-B-mediated inflamma-
tion was also identified as one of the most upregulated bio-
logical processes inmiR-10a knockdown cells. Consistently,
phosphorylation of IB is significantly up-regulated upon
miR-10a knockdown in human aortic endothelial cells, and
this is accompanied by the increased nuclear localization of
NF-B p65 and expression of pro-inflammatory biomark-
ers like TNF and interleukin-8 (IL-8) (63). This NF-B,
HOXA1 andmiR-10a relationship is therefore supportive of
a possible link between HOXA1 andmegakaryocytopoiesis
as well as inflammation.
The HOXA1 sequence shows an intriguing feature in
two His repeats. Among homopolymeric tracts, His repeats
are relatively rare (64) and it has been reported that only
86 human proteins contain stretches of five or more His
residues (65). The physicochemical properties of His make
it a versatile amino acid that can fulfill different roles, influ-
encing protein conformation and enzymatic activity. Such
His repeats can be found in Zn-finger domains that bind
promoter DNA (66). Nevertheless, the function of these
His repeats is underexplored. Variations in HOXA1 His re-
peat length have been reported in cases of autism in the
Japanese population (18) and His deletion variants within
the HOXA1 sequence have also been pointed to critically
influence the function of the HOXA1 protein (20). Here
we highlighted that the longer His repeat and the home-
odomain of HOXA1 are crucial for establishing contacts
with RBCK1 and TRAF2 and to activate NF-B. We
demonstrated that the HOXA1mutants lacking the longest
His repeat or the homeodomain are unable to activate NF-
B and to stimulate IL-8 secretion.
HOXA1 has been reported as a human mammary ep-
ithelial oncogene that modulates the STAT and the p44/42
MAP kinase pathways to promote cell survival, prolifera-
tion and relieves human mammary cells from contact inhi-
bition in vitro (11,13,16,53). Among the hallmaks of cancer,
we focused on the ability of cancer cells to lose contact in-
hibition that gives rise to focus formation (16,52) whereas
cell-to-cell contacts formed by normal epithelial cells when
they reach confluence operate to suppress further cell pro-
liferation. As the ability to HOXA1 to trigger foci forma-
tion in MCF7 cells has been described previously (16), we
here demonstrated that blocking the NF-B pathway abol-
ishes this foci formation related to HOXA1 expression. As
Figure 9. Model for theHOXA1-mediatedmodulation of theNF-Bpath-
way. Upon TNF stimulation, TNF binding to TNFR initiates the re-
cruitment of TRADD that further recruits cIAP1/2, RIPK1, TRAF2
and TRAF5 to form the TRADD-dependent complex. This leads to the
docking of TAK1 in complex with TAB2 and TAB3, allowing formation
of the IKK complex. The IKK complex phosphorylates IB, promoting
its proteasomal degradation, allowing NF-B release and finally its nu-
clear translocation to engage transcriptional programs. On the one hand,
HOXA1 enhances TRAF2 activity or stabilizes the TRADD-dependent
complex to activate the TNF/NF-Bpathway.On the other hand,RBCK1
inhibits HOXA1 as well as TAB2/3 to repress NF-B activation. In addi-
tion, RBCK1 and TRAF2 can compete with each other to bind either the
11-His repeat or the homeodomain of HOXA1 (not represented).
HOXA1 was also reported as increasing the proliferation
rate of human breast cells (11,16), we hereby demonstrated
that the inhibition of the NF-B pathway prevents HOXA1
to enhance proliferation signaling, leading to oncogenic
transformation (52). NF-B activation is then crucial for
HOXA1-mediated oncogenesis.
Together, our data are supportive of a model (Figure 9)
in which HOXA1 interacts with TRAF2 to stabilize the
TRADD-dependent complex and/or to enhance TRAF2
activity, triggering NF-B activation. On the other hand,
HOXA1 is inhibited by RBCK1 as RBCK1 expression re-
presses HOXA1-induced NF-B activation. HOXA1 could
also inhibit RBCK1 ability to mediate TAB2/3 degrada-
tion since the inhibitory input RBCK1 exerts on NF-B is
partially relieved by HOXA1. Thus, HOXA1 and RBCK1
could display reciprocally inhibitory influences. Finally,
HOXA1 proteins lacking the 11-His repeat or the home-
odomain are unable to activate NF-B because they can-
not bind TRAF2 and cannot inhibit RBCK1. Correlatively,
considering that RBCK1 and TRAF2 seem to bind the
same determinants of HOXA1, they could compete each
other for HOXA1 interaction.
While TNF or IL-1 exposure can lead to NF-B ac-
tivation, it could also activate other signaling routes like
the JNK, p38 MAPK, necrosis or apoptosis pathways that
share the need of the TRADD-related platform for com-
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plete activation (67). The ability ofHOXA1 to interfere with
those pathways remains to be further investigated, as well as
the possible physical association between HOXA1 and the
TRADD-dependent complex.
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